{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:47Z","timestamp":1794047447901,"version":"4.8.0"},"reference-count":40,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>B-cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-\u03baB activation. Inhibition of MALT1 in preclinical models has proven efficacious in many B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma. We sought to examine the role of MALT1 in B-ALL and determine the biological consequences of its inhibition. Targeting MALT1 with both Z-VRPR-fmk and MI-2 efficiently kills B-ALL cells independent of the cell-of-origin (pro, pre, mature) or the presence of the Philadelphia chromosome, and spares normal B cells. The mechanism of cell death was through apoptotic induction, mostly in cycling cells. The proteolytic activity of MALT1 can be studied by measuring its ability to cleave its substrates. Surprisingly, with the exception of mature B-ALL, we did not detect cleavage of MALT1 substrates at baseline, nor after proteasomal inhibition or following activation of pre-BCR. To explore the possibility of a distinct role for MALT1 in B-ALL, independent of signaling through BCR, we studied the changes in gene expression profiling following a 24-hour treatment with MI-2 in 12 B-ALL cell lines. Our transcriptome analysis revealed a strong inhibitory effect on MYC-regulated gene signatures, further confirmed by Myc protein downregulation, concomitant with an increase in the Myc degrader FBXW7. In conclusion, our evidence suggests a novel role for MALT1 in B-ALL through Myc regulation and provides support for clinical testing of MALT1 inhibitors in B-ALL.<\/jats:p>","DOI":"10.3324\/haematol.2023.283178","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:28:19Z","timestamp":1695914899000},"page":"1348-1358","source":"Crossref","is-referenced-by-count":2,"title":["Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application"],"prefix":"10.3324","volume":"109","author":[{"given":"Firas M.","family":"Safa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Fontan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Melnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lobelle-Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Mouawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Safah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik K.","family":"Flemington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"60211","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9):836-847.","DOI":"10.1056\/NEJMoa1609783"},{"key":"60212","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375(8):740-753.","DOI":"10.1056\/NEJMoa1509277"},{"key":"60213","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"60214","doi-asserted-by":"crossref","unstructured":"Herishanu Y, Perez-Galan P, Liu D. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011; 117(2):563-574.","DOI":"10.1182\/blood-2010-05-284984"},{"key":"60215","doi-asserted-by":"crossref","unstructured":"Treon SP, Tripsas CK, Meid K. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015; 372(15):1430-1440.","DOI":"10.1056\/NEJMoa1501548"},{"key":"60216","doi-asserted-by":"crossref","unstructured":"Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006; 107(8):3034-3044.","DOI":"10.1182\/blood-2005-09-3679"},{"key":"60217","doi-asserted-by":"crossref","unstructured":"Bertoni F, Rossi D, Zucca E. Recent advances in understanding the biology of marginal zone lymphoma. F1000Res. 2018; 7:406.","DOI":"10.12688\/f1000research.13826.1"},{"key":"60218","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"60219","doi-asserted-by":"crossref","unstructured":"Saba NS, Liu D, Herman SE. Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood. 2016; 128(1):82-92.","DOI":"10.1182\/blood-2015-11-681460"},{"key":"60220","doi-asserted-by":"crossref","unstructured":"Kohrer S, Havranek O, Seyfried F. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/ AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016; 30(6):1246-1254.","DOI":"10.1038\/leu.2016.9"},{"key":"60221","unstructured":"Saba NS, Angelova M, Lobelle-Rich PA, Levy LS. Disruption of pre-B-cell receptor signaling jams the WNT\/beta-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines. Leuk Res. 2015; S0145-2126(15):30355-30356."},{"key":"60222","doi-asserted-by":"crossref","unstructured":"Kim E, Hurtz C, Koehrer S. Ibrutinib inhibits pre-BCR(+) B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. 2017; 129(9):1155-1165.","DOI":"10.1182\/blood-2016-06-722900"},{"key":"60223","doi-asserted-by":"crossref","unstructured":"Xu Y, Hu J, Wang X. Overexpression of MALT1-A20-NF-kappaB in adult B-cell acute lymphoblastic leukemia. Cancer Cell Int. 2015; 15:73.","DOI":"10.1186\/s12935-015-0222-0"},{"key":"60224","doi-asserted-by":"crossref","unstructured":"Fontan L, Yang C, Kabaleeswaran V. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell. 2012; 22(6):812-824.","DOI":"10.1016\/j.ccr.2012.11.003"},{"key":"60225","doi-asserted-by":"crossref","unstructured":"Fontan L, Qiao Q, Hatcher JM. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest. 2018; 128(10):4397-4412.","DOI":"10.1172\/JCI99436"},{"key":"60226","doi-asserted-by":"crossref","unstructured":"Saba NS, Wong DH, Tanios G. MALT1 inhibition is efficacious in both na\u00efve and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Res. 2017; 77(24):7038-7048.","DOI":"10.1158\/0008-5472.CAN-17-2485"},{"key":"60227","doi-asserted-by":"crossref","unstructured":"Dai B, Grau M, Juilland M. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood. 2017; 129(3):333-346.","DOI":"10.1182\/blood-2016-05-718775"},{"key":"60228","doi-asserted-by":"crossref","unstructured":"Allen A, Gill K, Hoehn D. C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?. Leuk Res. 2014; 38(9):1061-1066.","DOI":"10.1016\/j.leukres.2014.06.022"},{"key":"60229","doi-asserted-by":"crossref","unstructured":"Ge Z, Guo X, Li J. Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia. Oncotarget. 2015; 6(39):42300-42311.","DOI":"10.18632\/oncotarget.5982"},{"key":"60230","doi-asserted-by":"crossref","unstructured":"Sheikh-Zeineddini N, Safaroghli-Azar A, Salari S, Bashash D. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: proposing a probable mechanism of action for 10058-F4. Eur J Pharmacol. 2020; 870:172821.","DOI":"10.1016\/j.ejphar.2019.172821"},{"key":"60231","doi-asserted-by":"crossref","unstructured":"Folgiero V, Sorino C, Pallocca M. Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia. EMBO Rep. 2018; 19(3):e44871.","DOI":"10.15252\/embr.201744871"},{"key":"60232","doi-asserted-by":"crossref","unstructured":"Wossning T, Herzog S, Kohler F. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006; 203(13):2829-2840.","DOI":"10.1084\/jem.20060967"},{"key":"60233","doi-asserted-by":"crossref","unstructured":"Xia M, David L, Teater M. BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL. Cancer Discov. 2022; 12(8):1922-1941.","DOI":"10.1158\/2159-8290.c.6549644"},{"key":"60234","doi-asserted-by":"crossref","unstructured":"Rebeaud F, Hailfinger S, Posevitz-Fejfar A. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat Immunol. 2008; 9(3):272-281.","DOI":"10.1038\/ni1568"},{"key":"60235","doi-asserted-by":"crossref","unstructured":"Ginster S, Bardet M, Unterreiner A. Two antagonistic MALT1 auto-cleavage mechanisms reveal a role for TRAF6 to unleash MALT1 activation. PLoS One. 2017; 12(1):e0169026.","DOI":"10.1371\/journal.pone.0169026"},{"key":"60236","doi-asserted-by":"crossref","unstructured":"Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000; 95(6):2104-2110.","DOI":"10.1182\/blood.V95.6.2104"},{"key":"60237","doi-asserted-by":"crossref","unstructured":"Yada M, Hatakeyama S, Kamura T. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23(10):2116-2125.","DOI":"10.1038\/sj.emboj.7600217"},{"key":"60238","doi-asserted-by":"crossref","unstructured":"Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008; 8(2):83-93.","DOI":"10.1038\/nrc2290"},{"key":"60239","doi-asserted-by":"crossref","unstructured":"Nahar R, Ramezani-Rad P, Mossner M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011; 118(15):4174-4178.","DOI":"10.1182\/blood-2011-01-331181"},{"key":"60240","unstructured":"National Cancer Institute SRP. Surveillance,Epidemiology, and End Results (SEER) Program]. National Cancer Institute, Surveillance Research Program. 2023. Publisher Full Text|"},{"key":"60241","doi-asserted-by":"crossref","unstructured":"Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013; 12(3):229-243.","DOI":"10.1038\/nrd3937"},{"key":"60242","doi-asserted-by":"crossref","unstructured":"Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013; 13(8):578-591.","DOI":"10.1038\/nri3487"},{"key":"60243","doi-asserted-by":"crossref","unstructured":"Kohrer S, Havranek O, Seyfried F. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/ AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016; 30(6):1246-1254.","DOI":"10.1038\/leu.2016.9"},{"key":"60244","doi-asserted-by":"crossref","unstructured":"Muschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 2015; 125(24):3688-3693.","DOI":"10.1182\/blood-2015-01-567842"},{"key":"60245","doi-asserted-by":"crossref","unstructured":"Kim E, Koehrer S, Rosin NY. Activity of Bruton\u2019s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL). Blood. 2012; 120(21):2569.","DOI":"10.1182\/blood.V120.21.2569.2569"},{"key":"60246","doi-asserted-by":"crossref","unstructured":"Kim E, Koehrer S, Wang Z. The PI3K delta inhibitor idelalisib interferes with pre-B cell receptor signaling in acute lymphoblastic leukemia (ALL): a new therapeutic concept. Blood. 2013; 122(21):2632.","DOI":"10.1182\/blood.V122.21.2632.2632"},{"key":"60247","doi-asserted-by":"crossref","unstructured":"Wang R, Zhang H, Xu J. MALT1 Inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia by blocking Notch1-induced NF-kappaB activation. Front Oncol. 2020; 10:558339.","DOI":"10.3389\/fonc.2020.558339"},{"key":"60248","doi-asserted-by":"crossref","unstructured":"Herman SE, Gordon AL, Hertlein E. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-6296.","DOI":"10.1182\/blood-2011-01-328484"},{"key":"60249","doi-asserted-by":"crossref","unstructured":"Hoellenriegel J, Coffey GP, Sinha U. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012; 26(7):1576-1583.","DOI":"10.1038\/leu.2012.24"},{"key":"60250","doi-asserted-by":"crossref","unstructured":"Herman SE, Gordon AL, Wagner AJ. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12):2078-2088.","DOI":"10.1182\/blood-2010-02-271171"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283178\/76146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283178\/76929","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11280\/76146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:57Z","timestamp":1794045897000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283178","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}